Highlights:

. The company is close to completing the 100 years of operations, while it has been market leader for many years. Further, the company has gained market share, despite entry and competition of new players.

. The company has recorded 14.5% growth in gross written premium to Rs 12823 crore in H1FY2018. As per the company, the non-life insurance industry is poised for strong growth and company would continue to play dominant role. The company expects the industry premium growth of 17-18% and expects to grow in line with the industry in FY2018.

. The company has posted strong 188% growth in its net profit to Rs 748.27 crore in Q2FY2018 and 161% jump to Rs 1247.68 crore in H1FY2018.

. As per the company, the improved profitability was driven by sharp decline in combined ratio to 112.57% in Q2FY2018 from 124.24% in Q2FY2017 and adjusted combined ratio to 91.45% from 103.65%. This led by decline in incurred claims ratio to 87.45% from 95.88%.

. The profitability of the company was also supported by improvement in expense ratio to 17.02% in Q2FY2018 from 21.65% in Q2FY2018.

. The company has improved RoE to 23.43% in Q2FY2018 from 9.14% in Q2FY2017.

. The solvency ratio of the company has improved to 2.24x end September 2017 from 2.2x end September 2016.

. For the half year ended September 2017, the company has improved combined ratio to 11.76% from 119.81% in H1FY2017, while the adjusted combined ratio dipped to 93.47% from 102.08%. the improvement in combined ratio is driven by dip in incurred claims ratio to 87.54% in H1FY2018 from 92.13% in H1FY2017.

. The company has also exhibited improvement in expense ratio to 16.59% in H1FY2018 from 20.73% in H1FY2017. The company has one of the lowest expense ratio in the industry, while expects to sustain improvement in expense ratio, going forward.

. The company has witnessed decline in employee count to 17500 end September 2017 from 20000 three years ago.

. The company has improved RoE to 19.98% in H1FY2018 from 8.52% in H1FY2017.

. The health insurance segment has been cause of concern for the company. However, the company improved loss ratio in the health insurance segment with price correction and improvement claim settlement process.

. The company has exhibited 16% decline in Q2FY2018, while claims have declined 10% in H1FY2018, while the company expects to continue decline in claims in the health insurance segment.

. On price correction front, the company has raise pricing of retail health insurance products in the range of 25% and 20-40% for corporate health insurance products.

. The loss ratio for retail health insurance have declined to 82% in H1FY2018 from 87% in H1FY2017, while the loss ratio for corporate health products has dipped to 110% from 125%, while its expected to dip to 100% by end March 2018.

. The investment income stood at Rs 1530 crore in Q2FY2018 and Rs 2778 crore in H1FY2018, of which approximately Rs 40% came from profit on sale of investment and balance from regular items in both Q2FY2018 and H1FY2018.

The networth of the company including fair value account stood at Rs 36573 crore, AUM at Rs 60573 crore and assets base at Rs 73714 crore end September 2017.